For patients with branch duct intraductal papillary mucinous neoplasms (BD-IPMNs, cysts), it is a challenge to identify those at high risk for malignant lesions. We sought to identify factors associated with development of pancreatic cancer, focusing on neoplasm growth rate.
A s a result of improved cross-sectional imaging technology, incidental pancreatic cystic neoplasms (PCNs) are identified in up to 2.6% of patients undergoing computed tomography (CT) scanning and 40% on magnetic resonance imaging (MRI). [1] [2] [3] [4] The most commonly encountered PCN is branch-duct intraductal papillary mucinous neoplasm (BD-IPMN). 5 Identification is important because BD-IPMN carries a risk of malignant transformation; therefore, a well-defined follow-up management plan is typically recommended for most patients. 6 Current management guidelines for IPMN [7] [8] [9] [10] [11] focus on morphologic features for risk stratification. However, numerous studies have demonstrated that morphologic features have only a moderate sensitivity and specificity to predict malignancy. [12] [13] [14] [15] [16] [17] [18] [19] [20] This indicates cyst features commonly surveyed (size, mural nodule, pancreatic duct dilation) are not reliable enough to adequately inform a decision of surgery or surveillance. Many patients with otherwise benign or indolent lesions undergo unnecessary surgery, and some cases of high-grade dysplasia or invasive carcinoma are missed. There is a clear need to improve risk stratification for patients with BD-IPMN.
Because most suspected BD-IPMNs are managed with radiographic surveillance, cyst growth rate is a potentially valuable metric. The aim of this study was to investigate cyst growth rate of BD-IPMNs as a noninvasive predictor of malignancy.
Methods

Study Design
This was a single-center retrospective review of patients at a large urban tertiary referral center. Patients were identified via a query of the electronic medical record by using a combination of International Classification of Diseases, 9th Revision code (577.2 Cyst of the Pancreas) and/or free text diagnosis entry ("IPMN" or "intraductal papillary mucinous neoplasm") during a 10-year time period (January 2003-2013). Institutional review board approval was obtained for this study.
Patient Characteristics
Adult patients older than 18 years with known or suspected BD-IPMN were identified. Subjects were included if they had a minimum of 2 contrastenhanced imaging studies at least 12 months apart (ie, CT, MRI with or without magnetic resonance cholangiopancreatography [MRCP], or MRCP). Patients were excluded if they had reports of earlier or later scans, but the imaging was not accessible. Patients who were symptomatic (ie, jaundice, pain) or had history of pancreatic cancer or pancreatic surgery were also excluded. Subjects with a history of acute or chronic pancreatitis were also excluded to exclude misclassified pseudocysts.
Cyst Characteristics
BD-IPMN was defined as a unilocular or multicystic lesion with at least 1 of the following features: (1) communicates with the main pancreatic duct (as seen on CT, MRCP, or endoscopic ultrasound); (2) multifocal in nature (ie, multiple cysts present throughout the pancreas); (3) clear, viscous fluid on fine-needle aspiration; (4) cyst fluid carcinoembryonic antigen >192 ng/mL; or (5) cyst fluid cytology consistent with IPMN. Cysts were excluded if they had a microcystic or honeycomb appearance typical of a serous cystadenoma or exhibited Fukuoka worrisome (ie, cyst size !3 cm, thickened/enhanced cyst wall, non-enhancing mural nodules, main pancreatic duct size of 5-9 mm, and abrupt change in duct caliber) or high-risk (ie, solid mass, obstructive jaundice, enhanced solid component, and main pancreatic duct size !10 mm) features on initial study.
Imaging Protocol
Two radiologists (P.A., K.L.) with expertise in pancreatic imaging reviewed all imaging studies. Maximum cyst size (x and y axes) was recorded in both the axial and coronal planes. Cyst size was obtained at 2 time points, the initial and the most recent crosssectional imaging study. Surveillance interval was defined as the time between these 2 scans and varied for each patient. When multifocal, the largest cyst was used. Growth rate was defined as the change in cyst size over the number of surveillance years.
Outcomes
The primary outcomes were (1) to determine growth rate of low-risk BD-IPMNs followed by radiographic surveillance and (2) assess whether cyst growth rate correlates with risk of development of high-risk features or pathology. The secondary outcome was to evaluate the impact of measuring BD-IPMNs in the axial vs coronal plane on cross-sectional imaging.
Statistical Analysis
All analyses were completed by using SAS version 9.4 (SAS Institute, Cary, NC). Two-sided P value less than .05 was defined the significance level in all statistical tests. Baseline characteristics of the study sample were provided as follows: mean and standard deviation were given for those normally distributed continuous variables, and median and interquartile range were given for those skewed distributed continuous variables. Characteristics were compared between those with and without worrisome features by using t test, Wilcoxon, c 2 , and Fisher exact test as appropriate. Unadjusted bivariate analyses comparing group differences included 2-sample t test or Wilcoxon Mann-Whitney test as appropriate. Descriptive statistics such as mean, standard deviation, median, and range were also provided in the tables. Univariate logistic regression models were built to predict the odds ratio (OR) of developing worrisome features based on the variables below. A multivariate model was not feasible here because of small sample size of the worrisome group.
Results
A total of 188 patients with BD-IPMN were identified and included in the analysis. Patient and cyst characteristics are described (Table 1) . Initial median cyst size was 11 Â 9 mm in the axial plane (n ¼ 188) and 11 Â 11 mm in the coronal plane (n ¼ 153). Final cyst size was 12.5 Â 10 mm in the axial plane (n ¼ 188) and 11 Â 12 mm in the coronal plane (n ¼ 176). The mean time between the initial and most recent scan was 50.34 AE 29.56 months. Median cyst growth rate was 0.29 mm/year (range, À3.6 to 11.65 mm/year). There were no significant differences in cyst size or cyst growth rate measured in all 4 directions. Median follow-up time was 55 months (12-163).
There were 12 patients who developed worrisome features: main pancreatic duct diameter 5-9 mm (n ¼ 1), thickened/enhancing cyst wall (n ¼ 4), cyst size !3 cm (n ¼ 3), cyst size !3 cm with thickened/enhancing cyst wall (n ¼ 2), and cyst size !3 cm with main pancreatic duct diameter 5-9 mm (n ¼ 1). No patients developed high-risk features. There were 4 patients who underwent surgical resection; 1 had developed worrisome features (Table 2) . No cancers developed during the follow-up period.
Cyst growth rate was greater in the 12 patients who developed worrisome features compared with the rest of the cohort (axial X 2.84 mm/year vs 0.23, P < .001; axial Y 1.02 vs 0.02, P ¼ .033; coronal X 1.21 vs 0.19, P ¼ .001; -, data not available. coronal Y 1.56 vs 0.00 (P < .001) ( Figure 1A ). Six of these 12 patients met criteria for developing worrisome features on the basis of cyst size >3 cm; additional analysis was performed after excluding these patients. A similar trend was seen where the 6 patients who developed worrisome features independent of cyst size had a greater growth rate compared with the rest of the cohort (axial X Baseline characteristics of the study sample overall and stratified by development of worrisome features are provided (Table 3) . Overall the 2 groups differed in their baseline cyst size; however, there was no difference in baseline age, body mass index, gender, family history, and smoking history. Results of univariate logistic regression model were consistent (Table 4) . Baseline cyst size and growth rate were significantly associated with the outcome, and as the cyst size/growth rate increased, the chance of developing worrisome features 
Discussion
This study demonstrates that BD-IPMNs with lowrisk features rarely have a significant change in size during follow-up of 5 years. Development of worrisome features is uncommon; however, when present, it is associated with a significantly higher cyst growth rate. A univariate regression analysis demonstrated that both cyst size and cyst growth rate were significantly associated with the development of worrisome features.
Among our cohort, those who developed worrisome features exhibited growth of 4 mm/year.
Previous studies have evaluated the role of cyst growth rate in BD-IPMNs. Kang et al 21 studied a group of 201 patients with low-risk BD-IPMN and median followup of 27.9 months and found that malignant cysts (n ¼ 8) grew at a greater rate than benign (4.1 versus 1.0 mm/year; P ¼ .001), and cysts that grew more than 2 mm/year had a higher 5-year risk of malignancy (45.5% vs 1.8%, P < .001). Another group performed a retrospective, multi-center study of 284 low-risk BD-IPMNs undergoing surveillance for a median follow-up of 56 months. 22 Cysts that developed into malignant IPMNs (n ¼ 9) grew at a faster rate compared with the benign (n ¼ 275) (18.6 vs 0.8 mm/year, P ¼ .05). Our study results demonstrate that cysts that develop Fukuoka worrisome features grow at a faster rate compared with the rest of the low-risk BD-IPMNs, independent of original cyst size. Each of the Fukuoka worrisome features has a well-described risk of malignancy: cyst size greater than 3 cm (OR, 62.4; 95% CI, 30.8-126.3), presence of a mural nodule (OR, 9.3; 95% CI, 5.3-16.1), and dilatation of the main pancreatic duct (OR, 7.27; 95% CI, 3.0-17.4). 23 Worrisome features may lead to an increased risk of developing cancer in select patients in the same way that the presence of high-risk features impacts survival. 24 Thus, our results support cyst growth rate as a useful noninvasive predictor of malignancy.
The present study illustrates that in general, low-risk BD-IPMNs grow at an extremely slow rate (w0.3 mm/ year), nearly one-third slower than described in previous studies. This finding might be accounted for by our inclusion of smaller cysts, where initial cyst size was 10 mm in the current study compared with the other studies that analyzed only cysts larger than 15 mm. Pergolini et al 25 recently demonstrated that in 109 patients with BD-IPMN with a cyst size 1.5 cm followed for more than 5 years, only a single cancer developed (0.9%), giving a negative predictive value for malignancy of 99% and sensitivity of 95% for cyst size 1.5 cm. Similarly, in our analysis of 188 patients with low-risk BD-IPMN where initial and final cyst size was <1.25 cm, no malignancies developed. A prospective study of 121 patients with BD-IPMN followed from 1999 to 2005 (median follow-up of 33 months) demonstrated an increase in cyst size to >5 mm to be the single significant factor associated with risk for malignant development. 26 Although the quoted risk of developing malignant IPMN in low-risk lesions is 3.7%-8% during a period of 10 years, no high-grade dysplasia or invasive carcinoma developed in our cohort of 188 patients. 6, 27 We were surprised to find that there was no difference when measuring cyst size in the axial versus coronal plane. Surveillance guidelines are largely predicated on cyst size; therefore, accurate measurements are crucial. Studies have showed considerable variability of up to 3 mm in pancreatic cyst size measurement on CT versus MRI 28 and poor interobserver agreement among radiologists. 29 These inconsistencies are problematic because both CT and MRI are accepted imaging modalities, and the guidelines do not specify how to record size from cross-sectional imaging studies. To the best of our knowledge, there is no published literature addressing this question. Our study results are unique in demonstrating that cyst size can be reliably measured in the axial and coronal planes in both the x and y directions.
The strengths of this study are the inclusion of a large cohort of low-risk BD-IPMNs representative of incidentally found cysts in the general population. Strict inclusion criteria were applied to capture only true "low risk" BD-IPMN. Two expert radiologists reviewed all images, and cyst size was measured in 4 directions.
Limitations include that this was a retrospective study with presumptive clinical and radiographic diagnosis of IPMN as well as small sample size and incomplete data. In addition, measurements were taken at only 2 time points rather than at multiple time points during the course of surveillance. The inclusion of additional time points may have resulted in more detail in the rapidity of growth over time rather than simply the absolute difference in size between index scan and final scan. In addition, patients had variable duration of surveillance. Importantly, there were only 12 patients out of 189 who met the primary outcome (development of worrisome or high-risk features). This very small number limits our conclusions regarding cyst growth rate and prevented multivariate analysis.
In summary, low-risk BD-IPMNs surveyed during a nearly 5-year period rarely show significant growth. Cyst size variability in different planes does not affect the outcome. The overall risk of developing worrisome features, high-risk features, or cancer is very low. However, those lesions that did exhibit worrisome features had a greater growth rate compared with lesions that remained at low risk. As such, BD-IPMNs that grow >2.5 mm/year may represent a subgroup of patients who warrant continued close radiographic surveillance.
